Your browser doesn't support javascript.
loading
Caregiver-reported symptom burden and preferences for therapeutic goals in pediatric primary sclerosing cholangitis.
Shifman, Holly Payton; Hatchett, Joanne; Pai, Ruth-Anne; Safer, Ricky; Gomel, Rachel; Vyas, Mary; Li, Michael; Lai, Jennifer C; Wadhwani, Sharad I.
Afiliación
  • Shifman HP; Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Hatchett J; Department of Pediatrics, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts, USA.
  • Pai RA; PSC Partners Seeking a Cure, Greenwood Village, Colorado, USA.
  • Safer R; PSC Partners Seeking a Cure, Greenwood Village, Colorado, USA.
  • Gomel R; PSC Partners Seeking a Cure, Greenwood Village, Colorado, USA.
  • Vyas M; PSC Partners Seeking a Cure, Greenwood Village, Colorado, USA.
  • Li M; PSC Partners Seeking a Cure, Greenwood Village, Colorado, USA.
  • Lai JC; Department of Medicine, University of California, San Francisco, San Francisco, California, USA.
  • Wadhwani SI; Department of Medicine, University of California, San Francisco, San Francisco, California, USA.
Article en En | MEDLINE | ID: mdl-38899591
ABSTRACT
This study analyzed qualitative and quantitative survey responses from 51 pediatric primary sclerosing cholangitis (PSC) patients and caregivers using the PSC Partners Patient Registry-Our Voices survey. The most common symptoms reported by children/caregivers include fatigue (71%), abdominal pain (69%), anxiety (59%), appetite loss (51%), insomnia (49%), and pruritus (45%). When experiencing symptoms at their worst, over half of patients/caregivers reported limitations in physically demanding activities (67%), work/school duties (63%), social life activities (55%), and activities for fun or exercise (53%). Over half of patients/caregivers expressed willingness to participate in clinical trials, however none reported ever participating in trials for new or investigational PSC drugs. This study revealed a substantial patient/caregiver-reported symptom burden for children with PSC that impacts quality of life and limits access to clinical trials. Future efforts should focus on developing patient-centered clinical endpoints for PSC trials, increasing trial availability for pediatric PSC patients, and reducing logistical barriers to trial involvement.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: J Pediatr Gastroenterol Nutr Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: J Pediatr Gastroenterol Nutr Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos